Nitto Denko Avecia vs PolyPeptide Group: CDMO Comparison
How does Nitto Denko Avecia compare to PolyPeptide Group for Oligo/ASO manufacturing?
Side-by-side comparison of Nitto Denko Avecia and PolyPeptide Group on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
On a 13-modality CDMO landscape, both Nitto Denko Avecia and PolyPeptide Group qualify as Oligo/ASO manufacturers; Nitto Denko Avecia carries the higher composite Signal Score for Oligo/ASO programs in this comparison.
What to evaluate for Oligo/ASO programs
Both Nitto Denko Avecia and PolyPeptide Group qualify as Oligo/ASO CDMOs. When choosing between them for Oligo/ASO programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Synthesis scale
Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.
Chemistry & conjugation
Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.
Purity & analytics
Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Nitto Denko Avecia vs PolyPeptide Group
How does Nitto Denko Avecia compare to PolyPeptide Group for Oligo/ASO manufacturing?
On CDMO Signal's composite Signal Score, Nitto Denko Avecia is 80/100 and PolyPeptide Group is 77/100; Nitto Denko Avecia has 4 FDA inspections on record vs 3 for PolyPeptide Group. Both are tracked in the CDMO Signal directory as Oligo/ASO CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Nitto Denko Avecia or PolyPeptide Group?
Both Nitto Denko Avecia and PolyPeptide Group maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Nitto Denko Avecia has 4 FDA inspections on record; PolyPeptide Group has 3.
Which is better for Oligo/ASO manufacturing — Nitto Denko Avecia or PolyPeptide Group?
Both Nitto Denko Avecia and PolyPeptide Group are tagged as Oligo/ASO CDMOs in our directory, so both are credible options for Oligo/ASO programs. The most important differentiator for Oligo/ASO selection is typically synthesis scale: Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Nitto Denko Avecia carries a Signal Score of 80/100 and PolyPeptide Group carries 77/100 — essentially tied for Nitto Denko Avecia. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →